Arrowhead Completes Enrollment in Phase 3 Zodasiran Trial for Rare Cholesterol Disorder
ARWR has more than doubled off its 52-week low of $15.01.
Summary
Arrowhead has fully enrolled its pivotal Phase 3 YOSEMITE study of zodasiran in homozygous familial hypercholesterolemia (HoFH), a rare genetic condition with limited treatment options. The trial enrolled 70 patients, up from the planned 60, reflecting strong physician and patient demand. Topline data are expected in mid-2027, with regulatory filings to follow if results are positive. This marks a key de-risking step for the zodasiran program, which targets ANGPTL3 via RNAi and has Orphan Drug Designation. The milestone follows recent commercial momentum for REDEMPLO and pipeline advances noted in the May 10-Q.
At the time of this announcement, ARWR was trading at $86.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1B. The 52-week trading range was $15.01 to $95.49. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.